Abstracts tagged "patient outcomes"

Abstract Number: 1392 • 2018 ACR/ARHP Annual Meeting
Decreased Injection Site Pain Associated with New Etanercept Formulation in Patients with Rheumatoid Arthritis or Psoriatic Arthritis
Stanley Cohen¹, Ahmed Samad², Elaine Karis², Bradley S. Stolshek², Mona Trivedi², Hao Zhang², Girish A. Aras², Greg Kricorian² and James Chung², ¹Metroplex Clinical Research Center, Dallas, TX, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Injection site pain (ISP) is a component of the patient experience with injectable drugs. A new formulation of etanercept was developed to reduce ISP.…
Abstract Number: 1407 • 2018 ACR/ARHP Annual Meeting
Differences in the Measurement Properties of the Patient-Reported Outcomes Measurement Information System Physical Function Short-Form 10a Among Racial/Ethnic Minorities with Rheumatoid Arthritis
Zara Izadi¹, Patricia Katz², Gabriela Schmajuk³, Julie Gandrup⁴, Jing Li⁵, Milena Gianfrancesco⁶ and Jinoos Yazdany⁷, ¹Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ²University of California San Francisco, San Francisco, CA, ³Medicine/Rheumatology, University of California - San Francisco, San Francisco, CA, ⁴Rheumatology, Odense University Hospital, Odense, Denmark, ⁵Medicine, UC San Francisco, San Francisco, CA, ⁶Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷University of California, San Francisco, San Francisco, CA
Background/Purpose: Most studies evaluating patient-reported outcomes such as the PROMIS Physical Function Short Form 10a (PF10a) in rheumatoid arthritis (RA) have been performed in white…
Abstract Number: 1602 • 2018 ACR/ARHP Annual Meeting
Disease Characteristics, Quality of Life, and Work Productivity By Enthesitis Sites: Real-World Data from the US Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J. Mease¹, Mei Liu², Sabrina Rebello³, Winnie Hua², Robert R. McLean², Peter Hur⁴ and Alexis Ogdie⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA, East Hanover, NJ, ⁵Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Prior studies showed psoriatic arthritis (PsA) patients with enthesitis had greater disease burden than patients without enthesitis, yet it is unknown whether the impact…
Abstract Number: 1643 • 2018 ACR/ARHP Annual Meeting
Psa Impact of Disease Questionnaire Scores Are Correlated with Disease Activity, As Measured By Cdapsa in Patients with Psa
Ana-Maria Orbai¹, Klaus Krüger², Frank Behrens³, Uta Kiltz⁴, Benoit Guerette⁵, Lillian Mellars⁵, Michele Brunori⁵ and Jürgen Wollenhaupt⁶, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Medical Centre of Rheumatology, Munich, Germany, ³Clinical Research Rheumatology and Fraunhofer Institute IMETranslation, Goethe University, Frankfurt, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Celgene Corporation, Summit, NJ, ⁶Schön-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany
Background/Purpose: We examined clinical correlations between disease activity, as measured with the Clinical Disease Activity for PsA (cDAPSA) components and PsA life impact/health-related quality of…
Abstract Number: 1689 • 2018 ACR/ARHP Annual Meeting
Explaining the Discrepancy between Physician and Patient-Reported Measures of Disease Activity in Systemic Lupus Erythematosus
Nathaniel J. Harris¹, Amanda M. Eudy² and Megan E. B. Clowse², ¹Department of Medicine, Duke University, Durham, NC, ²Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC
Explaining the Discrepancy between Physician and Patient-Reported Measures of Disease Activity in Systemic Lupus Erythematosus Background/Purpose: Patient-reported measures of disease activity provide useful adjuncts to…
Abstract Number: 2293 • 2018 ACR/ARHP Annual Meeting
Subcutaneous Intravenous Immunoglobulins in Idiopathic Inflammatory Myopathies: Analysis of a Monocentric Cohort
Emanuele Calabresi¹, Simone Barsotti², Elisa Cioffi³, Alessandra Tripoli¹, Andrea Delle Sedie¹, Laura Bazzichi⁴, Ornella Mazzarella¹, Rossella Neri⁴ and Marta Mosca¹, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Department of Medical Biotechnologies, University of Siena, Siena, Italy, ³Rheumatology Unit, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁴Rheumatology Unit, University of Pisa, PISA, Italy
Background/Purpose: Despite the absence of specific guidelines, the treatment with intravenous immunoglobulins (IvIg) is considered effective in patients with refractory idiopathic inflammatory myopathies (IIM). Recently,…
Abstract Number: 2359 • 2018 ACR/ARHP Annual Meeting
Systemic Lupus Erythematous Outcome Concerns: Identifying Pain As the Major Discrepancy between Rheumatologists and Patients
Isabela Bertoglio¹, Glaucia Abrahão¹, Eloisa Bonfa² and Michelle Lopes³, ¹Rheumatology, Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Now-a-days there is a growing trend of switching to a more patient-centered healthcare system, with a widespread use of patient-reported outcomes (PROs). However, most…
Abstract Number: 2360 • 2018 ACR/ARHP Annual Meeting
Perceptions of Patients with Rheumatoid Arthritis about Self-Assessment of Disease Activity after Watching an Educational Video: Qualitative Pilot Results from the Auto-DAS in Middle Eastern Arab Countries Study
Nelly Ziade¹, Sahar Saad², Manal al Mashaleh³, Lina el Kibbi⁴, Bassel el Zorkany⁵, Humeira Badsha⁶, Ghita Harifi⁶, Amani Daher⁷, Nelly Salloum⁸, Basel Masri⁹ and Thurayya Arayssi¹⁰, ¹Rheumatology, Saint-Joseph University, Beirut, Lebanon, ²Rheumatology, King Hamad University Hospital, Bahrain, Bahrain, ³Rheumatology, King Hussein Medical Center, Royal Medical Services, Amman, Jordan, ⁴Rheumatology, Specialized Medical Center, Riyadh, Saudi Arabia, ⁵Rheumatology, Cairo University, Cairo, Egypt, ⁶Dr. Humeira Badsha Medical Center, Dubai, United Arab Emirates, ⁷Medicine, Saint-Joseph University, Beirut, Lebanon, ⁸Registered Nurse, Beirut, Lebanon, ⁹Rheumatology, Jordan Hospital, Amman, Jordan, ¹⁰Medicine, Weill Cornell Medicine-Qatar, Doha, Qatar
Background/Purpose: Empowering RA patients through education is linked to improved adherence, treatment decisions and speeding up the assessment process during consultation. The purpose of the…
Abstract Number: 2369 • 2018 ACR/ARHP Annual Meeting
Patients Preference Goes to MTX Autoinjectors over Prefilled Syringes: Results from a Phase III Trial
Alain Saraux¹, Christophe Hudry², Elena Zinovieva³, Agnès Courbeyrette⁴ and Hélène Herman-Demars³, ¹Rheumatology, CHU Brest, Brest, France, ²AP-HP Hôpital Cochin, Paris, France, ³Medical Department Nordic Pharma, Paris, France, ⁴Medical Departement, Nordic Pharma, Paris, France
Background/Purpose: The offer of injectable MTX worldwide expanded during past few years with different types of enhanced devices such as prefilled syringes and autoinjector pens.…
Abstract Number: 2470 • 2018 ACR/ARHP Annual Meeting
The Impact of Frailty on Changes in Physical Function Among Adults with Rheumatoid Arthritis
James Andrews¹, Laura Trupin², Catherine Hough¹, Edward H. Yelin³ and Patricia Katz², ¹Medicine, University of Washington, Seattle, WA, ²University of California San Francisco, San Francisco, CA, ³Medicine/Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Frailty is a state of excess vulnerability to stressors and is associated with increased risk of poor health outcomes including physical disability. Frailty and…
Abstract Number: 2577 • 2018 ACR/ARHP Annual Meeting
Long-Term Effect of Ixekizumab on Patient-Reported Outcomes in Patients with Psa and Inadequate Response to TNF Inhibitors: 2-Year Follow-up from a Phase 3 Study
Anthony Turkiewicz¹, Amanda M. Gellett², Lisa Kerr², Julie Birt² and Jordi Gratacos³, ¹Rheumatology Associates, Birmingham, AL, ²Eli Lilly and Company, Indianapolis, IN, ³Rheumatology, Hospital Parc Taulí, Sabadell - Barcelona, Spain
Background/Purpose: PsA is a chronic and complex inflammatory disease with both articular and extra-articular symptoms, including joint pain, enthesitis, dactylitis, fatigue, and skin and nail…
Abstract Number: 1100 • 2017 ACR/ARHP Annual Meeting
Communication between Inpatient and Outpatient Specialty Clinicians: Developing a Better Understanding of Patients with Rheumatoid Arthritis Who Are Admitted to the Hospital
Abraham Tacang¹, Christina Downey², Alfred Denio¹, Eric Newman³ and Lisa L. Schroeder⁴, ¹Rheumatology, Geisinger Medical Center, Danville, PA, ²Geisinger Medical Center, Danville, PA, ³Department of Rheumatology, Geisinger Medical Center, Danville, PA, ⁴Rheumatology, Geisinger Health System, Danville, PA
Background/Purpose: Effective communication is essential in caring for medically complex patients with rheumatoid arthritis (RA). Communication between clinicians becomes even more crucial when a patient…
Abstract Number: 1241 • 2017 ACR/ARHP Annual Meeting
Understanding Differences in Patient Definitions of RA Flares Using Omeract Core Domains
Gabriela L. Maica¹, Michelle Frits², Christine Iannaccone³, Taysir G. Mahmoud⁴, Clifton O. Bingham III⁵, Vivian P. Bykerk⁶, Michael Weinblatt⁷ and Nancy A. Shadick⁸, ¹Department of Rheumatology, Allergy, and Immunology, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Rheumatology, Johns Hopkins University, Baltimore, MD, ⁶2-005, Mt Sinai Hospital, Toronto, ON, Canada, ⁷Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁸Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Flare is an important, distinct feature of RA, often rendering patients immobile and contributing to a poor quality of life. Recently, there has been…
Abstract Number: 1248 • 2017 ACR/ARHP Annual Meeting
Evaluation of Validated Patient Reported Outcome Measures to Assess Sensitivity to Change in Patients with Systemic Sclerosis and Gastroesophageal Reflux Disease —a Scleroderma Clinical Trials Consortium Collaborative Project
Zsuzsanna McMahan¹, Tracy M. Frech², David Lim³, Veronica J. Berrocal⁴, Cosimo Bruni⁵, Marco Matucci-Cerinic⁶, Vanessa Smith⁷, Karin Melsons⁸, Susanna Proudman⁹, Jinyu Zhang¹⁰, Fabian A Mendoza¹¹, Melanie Woods³ and Dinesh Khanna³, ¹Department of Internal Medicine, Johns Hopkins University, Baltimore, MD, ²Division of Rheumatology, University of Utah, Salt Lake City, UT, ³University of Michigan, Ann Arbor, MI, ⁴Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁵Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Firenze, Italy, ⁶Dept of Medicine/Div of Rheum, University of Florence, Firenze, Italy, ⁷Faculty of Internal Medicine, Ghent University, Ghent, Belgium, ⁸Ghent University, Gent, Belgium, ⁹Discipline of Medicine, University of Adelaide, Adelaide, Australia, ¹⁰Thomas Jefferson University, Philadelphia, PA, ¹¹Jefferson Institute of Molecular Medicine and Scleroderma Center, Rheumatology Division, Department of Medicine, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: The UCLA SCTC GIT 2.0 and NIH PROMIS GI Symptoms Scales are validated in scleroderma to assess patient-reported gastrointestinal (GI) involvement. We sought to…
Abstract Number: 1261 • 2017 ACR/ARHP Annual Meeting
The Effects of Disease Burden, Helplessness, and Pain on Depressive Symptoms in Rheumatoid Arthritis and Systemic Lupus Erythematosus
Sera Ramadan¹, Perry M. Nicassio², George Karpouzas³ and Sarah Ormseth⁴, ¹Internal Medicine, Dignity Health St. Mary Medical Center, Long Beach, CA, ²Cousins Center for PNI, UCLA, LA, CA, ³Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ⁴Rheumatology, Harbor-UCLA Medical Center, Torrance, CA
Background/Purpose: This research tested an integrated framework examining patient global assessment of disease activity (PtGA), maladaptive illness beliefs and pain as determinants of mood disturbance…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].